Cellectar BioSciences

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cellectar BioSciences reports strong Q1 results and eyes FDA submission

Cellectar BioSciences is well-positioned with strong financial backing and promising product developments. Challenges include financial losses, pricing strategy, and market competition. Opportunities lie in upcoming data releases, FDA submission, and global partnerships.

Cellectar BioSciences reports strong Q2 performance and prepares for NDA submission

Cellectar BioSciences showcased strong financial performance and promising trial results in Q2 2024.
While facing challenges in financial restatements and analyst inquiries, the company is progressing well with NDA preparations.
The company's confidence in the NDA filing, supported by robust data, highlights growth opportunities in addressing unmet medical needs.

Cellectar BioSciences excels in Q3 with strong data and growth opportunities

Cellectar BioSciences showcased strong performance in the CLOVER-WaM study and financial stability with a cash position of $34.3 million.
The company's focus on iopofosine I 131's potential in WM treatment and strategic collaborations highlight promising growth opportunities.
However, challenges lie in addressing FDA confirmatory studies, managing funding needs, and balancing research efforts for solid tumors and WM treatment.
Overall, Cellectar's value proposition remains strong, with upcoming product launches and a clear commercialization strategy in place.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference to be held from February 16-18, 2021.

Cellectar to Present at BIO CEO & Investor Digital Conference

Benefits include 10 years of market exclusivity in the European Union Benefits include 10 years of market exclusivity in the European Union

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to offer and sell shares of its common stock and common stock equivalents in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Cellectar Biosciences, Inc. (NASDAQ:CLRB), so let's take a closer look at the sentiment that surrounds it in the current quarter.

Is Cellectar Biosciences (CLRB) A Good Stock To Buy According To Hedge Funds?

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

American Public Education

Aqua Metals

Beazer Homes USA

The dollar has not only strengthened in recent times but it seems there is even more room for growth. So, let's find out which stocks stand to benefit from dollar's comeback.

5 Stocks to Invest in as Dollar Gets Its Mojo Back

Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look

40% overall response rate (ORR) with a total administered dose of 60 mCi or greater 40% overall response rate (ORR) with a total administered dose of 60 mCi or greater

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

American States Water

Civeo

Kindred Biosciences

Portland General Electric

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Play Rising P/E Investing With These Top 5 Stocks

Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM)

Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA

FLORHAM PARK, N.J., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

AcelRx Pharmaceuticals

BioDelivery Sciences

Benefitfocus

Alliant Energy

What Bargain Hunting? Tap 5 Stocks With Rising P/E

Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM) Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)

Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

Cellectar Biosciences (NASDAQ: CLRB) shares are trading higher on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and $5 price target.

Why Cellectar Biosciences Stock Is Trading Higher Today

FLORHAM PARK, N.J., July  01, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has appointed Dr. John Friend as chief medical officer, effective immediately.

Cellectar Appoints Dr. John Friend as Chief Medical Officer

Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

FLORHAM PARK, N.J., June  05, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of $20.0 million prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

FLORHAM PARK, N.J., June  03, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $20.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

Designation Comes with Financial and Scientific Incentives Designation Comes with Financial and Scientific Incentives

Cellectar Granted SME Status by the European Medicines Agency

FLORHAM PARK, N.J., May  26, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more. CLR 131 is the company’s small-molecule, cancer-targeting radiotherapeutic Phospholipid Drug Conjugate™ (PDC™) designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. It is currently being evaluated in Cellectar’s ongoing Phase 2 CLOVER-1 clinical study in patients with relapsed or refractory multiple myeloma and lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia.

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125 Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

FLORHAM PARK, N.J., Jan.  07, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer.

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

FLORHAM PARK, N.J., Jan.  06, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131 in Lymphoplasmacytic Lymphoma (LPL). CLR 131 is the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate currently in a Phase 2 clinical study in relapsed or refractory select B-cell lymphomas, including Lymphoplasmacytic Lymphoma (LPL).

News for Cellectar BioSciences Stock (CLRB)